Abeona Therapeutics FY2022 net loss narrows to $43.5M; EB-101 BLA submission on track

ABEONA THERAPEUTICS INC.

Net loss $43.5M ($5.53/share) vs $84.9M ($21.57/share) in FY2021 as expense reductions offset lower revenue.
Cash of $52.5M at Dec 31, 2022 ($50.9M at Dec 31, 2021); expected to fund operations into Q3 2024.
Plans to submit BLA for EB-101 (RDEB) to FDA in late Q2/early Q3 2023, based on positive Phase 3 VIITAL results.
Appointed Dmitriy Grachev as CMO; Madhav Vasanthavada as VP Business Development; Amanda Moore promoted to VP.
Completed $35M private placement in November 2022 with institutional investors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ABEONA THERAPEUTICS INC. reported full year 2022 results: revenue $1.4 million, net income $5.53 loss per common share.

Period: full year 2022
Revenue: $1.4 million
Net income: $5.53 loss per common share
Result: reported results

Exact text from the filing

License and other revenues for the year ended December 31, 2022 were $1.4 million

View on SEC.gov

52 earnings releases filed in the last 30 days. Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-009382

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.